Alamar Biosciences, Inc.(ALMR)

Biotechnology · Fremont, CA

$34.19-3.94 (-10.33%)

Delayed quote: Oct 6, 2026, 2:20 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T18:20:23.066Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:20:23.066Z.

Quote observation: 2026-10-06T18:20:02.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 2,369,749,278
Total debt · period ending 2026-06-30: 51,406,000
Cash · period ending 2026-06-30: 132,969,000

FMP input reference: 026981202cadb8e73b6cbd63f18abfa8ffa74fea80ac6bbb32512047e0825b9f

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALMR EBITDA Yield Metrics

EBITDA YIELD

N/A

ALMR Competitors' EBITDA Yield

ALMR

Alamar Biosciences, Inc.

Current

Market Cap

$2.37B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADMA

ADMA Biologics, Inc.

vs ALMR

Market Cap

$2.36B

EBITDA Yield

9.30%

TTM Avg

7.20%

3Y Avg

4.06%

5Y Avg

4.06%

RXRX

Recursion Pharmaceuticals, Inc.

vs ALMR

Market Cap

$2.39B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLOV

Clover Health Investments, Corp.

vs ALMR

Market Cap

$2.40B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRIX

Nurix Therapeutics, Inc.

vs ALMR

Market Cap

$2.34B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LQDA

Liquidia Corporation

vs ALMR

Market Cap

$2.35B

EBITDA Yield

7.77%

TTM Avg

1.47%

3Y Avg

1.47%

5Y Avg

1.47%

UFPT

UFP Technologies, Inc.

vs ALMR

Market Cap

$2.33B

EBITDA Yield

4.90%

TTM Avg

5.87%

3Y Avg

4.90%

5Y Avg

5.16%

IRON

Disc Medicine, Inc.

vs ALMR

Market Cap

$2.42B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SUPN

Supernus Pharmaceuticals, Inc.

vs ALMR

Market Cap

$2.44B

EBITDA Yield

N/A

TTM Avg

2.95%

3Y Avg

5.56%

5Y Avg

5.89%

HRMY

Harmony Biosciences Holdings, Inc.

vs ALMR

Market Cap

$2.29B

EBITDA Yield

13.54%

TTM Avg

15.75%

3Y Avg

13.75%

5Y Avg

10.29%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Alamar Biosciences, Inc. (ALMR)	$2.37B	N/A	N/A	N/A	N/A
ADMA Biologics, Inc. (ADMA)vs ›	$2.36B	9.30%	7.20%	4.06%	4.06%
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.39B	N/A	N/A	N/A	N/A
Clover Health Investments, Corp. (CLOV)vs ›	$2.40B	N/A	N/A	N/A	N/A
Nurix Therapeutics, Inc. (NRIX)vs ›	$2.34B	N/A	N/A	N/A	N/A
Liquidia Corporation (LQDA)vs ›	$2.35B	7.77%	1.47%	1.47%	1.47%
UFP Technologies, Inc. (UFPT)vs ›	$2.33B	4.90%	5.87%	4.90%	5.16%
Disc Medicine, Inc. (IRON)vs ›	$2.42B	N/A	N/A	N/A	N/A
Supernus Pharmaceuticals, Inc. (SUPN)vs ›	$2.44B	N/A	2.95%	5.56%	5.89%
Harmony Biosciences Holdings, Inc. (HRMY)vs ›	$2.29B	13.54%	15.75%	13.75%	10.29%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ALMR EBITDA Yield Metrics

ALMR Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics